FORXIGA (AstraZeneca Pty Ltd)
Product name
FORXIGA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
dapagliflozin propanediol monohydrate
Registration type
EOI
Indication
Heart failure
FORXIGA (tablet)is indicated in adults for the treatment of symptomatic heart failure with reduced ejection fraction, as an adjunct to standard of care therapy (see section 5.1 Pharmacodynamic properties).